|Oliceridine (TRV130)||Phase 3||Mu-receptor||Moderate to
|TRV734||Phase 1||Mu-receptor||Moderate to
Our pipeline consists of innovative product candidates focused in areas of acute care where current options leave significant unmet medical need:
Oliceridine (TRV130), our lead product candidate with FDA Breakthrough Therapy Designation, is a next generation IV analgesic currently in Phase 3 testing for the management of moderate-to-severe acute pain.
Oliceridine was specifically designed to improve on conventional IV opioid pharmacology, by binding to the same receptor as conventional opioids and selectively activating pain-relieving pathways, while avoiding the pathway associated with opioid-related adverse effects. Based on clinical trial results so far, oliceridine’s profile suggests that it will provide rapid and effective pain relief while potentially setting a new standard for opioid tolerability.
Our pipeline also includes several product candidates we have identified as potential best-in-class or first-in-class therapies to address a variety of serious unmet medical needs. TRV734 has completed Phase 1 studies for the oral treatment of acute and chronic pain; TRV250 is in preclinical development for the treatment of migraines; and TRV027 recently was evaluated in a Phase 2b study for the treatment of acute heart failure.
Copyright © Trevena, Inc.